BlackRock Fund Advisors recently announced the acquisition of new stake in Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX). The institutional investor has increased its shareholding in the Healthcare company by 0.83% to 6.5 million shares with purchase of 53576.0 shares. This fresh investment now brings its stake to 6.28% valued currently at $27.95 million. In addition, Armistice Capital LLC raised its holdings by 0.8 million to 6.2 million shares. And Morgan Stanley Smith Barney LLC (.. has lifted its position by 2.95% or 78837.0 shares – to 2.75 million shares.
With over 1.93 million Catalyst Pharmaceuticals Inc. (CPRX) shares trading Tuesday and a closing price of $3.13 on the day, the dollar volume was approximately $6.05 million. The shares have shown a negative weekly performance of -6.29% and its price on 09/01/20 lost nearly -4.57%. Currently, there are 103.42M common shares owned by the public and among those 96.33M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 6 analysts who have offered their price forecasts for CPRX have a consensus price objective of $7.58. The analysts have set the share’s price value over the next 12 months at a high of $9.00 and a low of $6.00 should the stock experience a downside. But an upside of 65.22% will see the stock hit the forecast high price target while mean target price for the stock is $8.00.
Insiders at the company have transacted a total of 8 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 5 of these insider trades were purchases, accounting for 370,000 shares. Insider sales of the common stock occurred on 3 occasions, with total insider shares sold totaling 350,000 shares.
The top 3 mutual fund holders in Catalyst Pharmaceuticals Inc. are SPDR S&P Biotech ETF, Vanguard Total Stock Market Index, and iShares Russell 2000 ETF. SPDR S&P Biotech ETF owns 5.16 million shares of the company’s stock, all valued at over $22.2 million. The company sold 51723.0 shares recently to bring their total holdings to about 4.99% of the shares outstanding. iShares Russell 2000 ETF sold 95676.0 shares to bring its total holdings to over 2.04 million shares at a value of $8.79 million. iShares Russell 2000 ETF now owns shares totaling to 1.98% of the shares outstanding.
Shares of Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) opened at $3.2526, down -$0.03 from a prior closing price of $3.28. However, the script later closed the day at $3.13, down -4.57%. The company’s stock has a 5-day price change of -6.29% and -29.66% over the past three months. CPRX shares are trading -16.53% year to date (YTD), with the 12-month market performance down to -48.86% lower. It has a 12-month low price of $2.55 and touched a high of $7.67 over the same period. Currently, 1.93 million shares have been traded, compared to an average intraday trading volume of 2.00 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -13.14%, -27.35%, and -27.15% respectively.
Institutional ownership of Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) shares accounts for 63.70% of the company’s 103.42M shares outstanding. Mutual fund holders own 23.83%, while other institutional holders and individual stakeholders account for 39.19% and 15.35% respectively.
It has a market capitalization of $314.13M and a beta (3y monthly) value of 1.55. The stock’s trailing 12-month PE ratio is 8.01, while the earnings-per-share (ttm) stands at $0.39. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.48% over the week and 5.82% over the month.
Analysts forecast that Catalyst Pharmaceuticals Inc. (CPRX) will achieve an EPS of $0.09 for the current quarter, $0.12 for the next quarter and $0.41 for 2021. The lowest estimate earnings-per-share for the quarter is $0.07 while analysts give the company a high EPS estimate of $0.11. Comparatively, EPS for the current quarter was $0.13 a year ago. Earnings per share for the fiscal year are expected to increase by 190.70%, and 4.27% over the next financial year.
Specifically, 6 Wall Street analysts polled rate the stock as a buy, while 0 of the 6 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the CPRX, a number of firms have released research notes about the stock. Cantor Fitzgerald stated their Overweight rating for the stock in a research note on September 21, 2018, with the firm’s price target at. Piper Jaffray coverage for the Catalyst Pharmaceuticals Inc. (CPRX) stock in a research note released on September 07, 2018 offered a Overweight rating with a price target of. Piper Jaffray was of a view on October 05, 2016 that the stock is Overweight, while Piper Jaffray gave the stock Neutral rating on April 26, 2016, issuing a price target of $6- $1. ROTH Capital on their part issued Buy rating on September 30, 2014.